Serum concentrations and effects of gabapentin and vigabatrin: Observations from a dose titration study

Therapeutic Drug Monitoring

Volumn 25, Issue 4, 2003, Pages 457-462

  Lindberger, Martin ^a   Luhr, Owe ^c   Johannessen, Svein I ^b   Larsson, Sirkku ^c   Tomson, Torbjörn ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b National Center for Epilepsy   (Norway)

^c Karolinska Hospital ^*

Author keywords

Gabapentin; Serum concentrations; Therapeutic monitoring; Vigabatrin

Indexed keywords

CARBAMAZEPINE; CLONAZEPAM; GABAPENTIN; OXCARBAZEPINE; PRIMIDONE; VALPROIC ACID; VIGABATRIN;

ADD ON THERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE CONTROL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MONITORING; FATIGUE; FEMALE; FOCAL EPILEPSY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEIZURE; VERTIGO;

ACETIC ACIDS; AMINES; ANTICONVULSANTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOHEXANECARBOXYLIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG MONITORING; EPILEPSIES, PARTIAL; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; VIGABATRIN;

EID: 0041766232     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200308000-00007     Document Type: Article

References (22)

1. Tomson T, Johannessen SI. Therapeutic monitoring of the new antiepileptic drugs. Eur J Clin Pharmacol. 1999;55:697-705.
2. Brodie MJ. Routine measurement of new antiepileptic drug concentrations: a critique and a prediction. In: French J, Leppik I, Dichter MA, eds. Antiepileptic Drug Development. Advances in Neurology, vol 76. Philadelphia: Lippincott-Raven, 1998, p 22:223.
3. Lindberger M, Alenius M, Frisén L, et al. Gabapentin versus vigabatrin as first add-on for patients with partial seizures that failed to respond to monotherapy: A randomized, double-blind, dosetitration study. Epilepsia. 2000;41:1289-1295.
4. Löscher W, Fassbender CP, Gram L, et al. Determination of GABA and vigabatrin in human plasma by a rapid and simple HPLC method: correlation between clinical response to vigabatrin and increase in plasma GABA. Epilepsy Res. 1993;14:245-255.
5. Forrest G, Sills GJ, Leach JP, et al. Determination of gabapentin in plasma by high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1996;681:421-425.
6. Kälviäinen R, Nousiainen I, Mäntyjärvi M, et al. Vigabatrin, a GABA-ergic antiepileptic drug, causes concentric visual field defects. Neurology. 1999;53:922-926.
7. Jung MJ, Lippert B, Metcalf BW, et al. Gamma-vinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice. Neurochemistry. 1977;29:797-802.
8. Ben-Menachem E. Vigabatrin: Chemistry, absorption, distribution, and elimination. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic Drugs, 4th ed. New York: Raven Press, 1995, pp 915-923
9. Gram L, Lyon BB, Dam M. Gamma-vinyl-GABA: A single blind trial in patients with epilepsy. Acta Neurol Scand. 1983;68:34-39.
10. Armijo JA, Cuadrado A, Bravo J, et al. Vigabatrin serum concentration to dosage ratio: Influence of age and associated drugs. Ther Drug Monit. 1997;19:491-498.
11. Patsalos PN. New antiepileptic drugs. Ann Clin Biochem. 1999;36:10-19.
12. May TW, Rambeck B, Jürgens U. Serum concentration of gabapentin in epileptic patients. Epilepsia. 1997;38(suppl 3):147.
13. Besag FMC, Berry DJ, Aylett SA, et al. Serum gabapentin levels continue to increase with dose in the high-range in children and teenagers. Epilepsia. 2000;41(suppl):147.
14. Gidal BE, Radulovic LL, Kruger S, Rutecki P, Pitterle M, Bockbrader HN. Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability. Epilepsy Res. 2000;40:123-127.
15. Ouellet D, Bockbrader HN, Wesche DL, et al. Population pharamacokinetics in infants and children. Epilepsy Res. 2001;47:229-241.
16. Beran RG, Berry D, Plunkett M. Gabapentin pharmacokinetics. Epilepsia. 1998;39(suppl 2):S68.
17. Sivenius J, Kalviainen R, Ylinen A, et al. A double-blind study of gabapentin in the treatment of partial seizures. Epilepsia. 1991;32:539-542.
18. Wilson EA, Sills GJ, Forrest G, et al. High-dose gabapentin in refractory epilepsy: Clinical observations in 50 patients. Epilepsy Res. 1998;29:161-166.
19. Riekkinen PJ, Ylinen A, Halonen T, et al. Cerebrospinal fluid GABA and seizure control with vigabatrin. Br J Clin Pharmacol. 1989;27:87-94.
20. Arteaga R, Herranz JL, Valdizán EM, et al. γ-Vinyl GABA (Vigabatrin): Relationship between dosage, plasma concentrations, platelet GABA-transaminase inhibition, and seizures reduction in epileptic children. Epilepsia. 1992;33:923-931.
21. Löscher W, Fassbender CP, Gram L, et al. Determination of GABA and vigabatrin in human plasma by a rapid and simple HPLC method: correlation between clinical repsonse to vigabatrin and increase in plasma GABA. Epilepsy Res. 1993;14:245-255.
22. Erdal J, Gram L, Alving J, et al. Changes in plasma GABA concentration during vigabatrin treatment of epilepsy: a prospective study. Epilepsy Res. 1999;34:145-150.